Use of tafenoquine to treat a patient with relapsing babesiosis with clinical and molecular evidence of resistance to azithromycin and atovaquone

Luis A. Marcos; Annie Leung; Laura Kirkman; Gary P. Wormser

doi:10.1016/j.idcr.2022.e01460

Use of tafenoquine to treat a patient with relapsing babesiosis with clinical and molecular evidence of resistance to azithromycin and atovaquone

Luis A. Marcos
, Annie Leung
, Laura Kirkman
, Gary P. Wormser

Infectious Diseases

Stony Brook University

Cornell University
New York Medical College

Research output: Contribution to journal › Article › peer-review

28 Scopus citations

Abstract

Tafenoquine is a highly effective treatment for Babesia microti infections in animal models. An immunocompromised patient infected by a strain of B. microti that was at least partially resistant to both azithromycin and atovaquone was treated with tafenoquine. Systematic clinical studies using tafenoquine for treating other patients with babesiosis should be considered.

Original language	English
Article number	e01460
Journal	IDCases
Volume	27
DOIs	https://doi.org/10.1016/j.idcr.2022.e01460
State	Published - Jan 2022

Keywords

Antibiotic resistance
Babesia microti
Babesiosis
Rituximab
Tafenoquine

Access to Document

10.1016/j.idcr.2022.e01460

Cite this

@article{a72d158e8d4d49d080f4b44d40dd77a2,

title = "Use of tafenoquine to treat a patient with relapsing babesiosis with clinical and molecular evidence of resistance to azithromycin and atovaquone",

abstract = "Tafenoquine is a highly effective treatment for Babesia microti infections in animal models. An immunocompromised patient infected by a strain of B. microti that was at least partially resistant to both azithromycin and atovaquone was treated with tafenoquine. Systematic clinical studies using tafenoquine for treating other patients with babesiosis should be considered.",

keywords = "Antibiotic resistance, Babesia microti, Babesiosis, Rituximab, Tafenoquine",

author = "Marcos, \{Luis A.\} and Annie Leung and Laura Kirkman and Wormser, \{Gary P.\}",

note = "Publisher Copyright: {\textcopyright} 2022",

year = "2022",

month = jan,

doi = "10.1016/j.idcr.2022.e01460",

language = "English",

volume = "27",

journal = "IDCases",

issn = "2214-2509",

publisher = "Elsevier Ltd.",

}

TY - JOUR

T1 - Use of tafenoquine to treat a patient with relapsing babesiosis with clinical and molecular evidence of resistance to azithromycin and atovaquone

AU - Marcos, Luis A.

AU - Leung, Annie

AU - Kirkman, Laura

AU - Wormser, Gary P.

PY - 2022/1

Y1 - 2022/1

N2 - Tafenoquine is a highly effective treatment for Babesia microti infections in animal models. An immunocompromised patient infected by a strain of B. microti that was at least partially resistant to both azithromycin and atovaquone was treated with tafenoquine. Systematic clinical studies using tafenoquine for treating other patients with babesiosis should be considered.

AB - Tafenoquine is a highly effective treatment for Babesia microti infections in animal models. An immunocompromised patient infected by a strain of B. microti that was at least partially resistant to both azithromycin and atovaquone was treated with tafenoquine. Systematic clinical studies using tafenoquine for treating other patients with babesiosis should be considered.

KW - Antibiotic resistance

KW - Babesia microti

KW - Babesiosis

KW - Rituximab

KW - Tafenoquine

UR - https://www.scopus.com/pages/publications/85125251191

U2 - 10.1016/j.idcr.2022.e01460

DO - 10.1016/j.idcr.2022.e01460

M3 - Article

SN - 2214-2509

VL - 27

JO - IDCases

JF - IDCases

M1 - e01460

ER -

Use of tafenoquine to treat a patient with relapsing babesiosis with clinical and molecular evidence of resistance to azithromycin and atovaquone

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this